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Abstract
Hsp90 isoform-selective inhibition is highly desired as it can potentially avoid the toxic side-
effects of pan-inhibition. The current study developed selective inhibitors of one such isoform,
Grp94, predicated on the chimeric and pan-Hsp90 inhibitor, radamide (RDA). Replacement of the
quinone moiety of RDA with a phenyl ring (2) was found to be better suited for Grp94 inhibition
as it can fully interact with a unique hydrophobic pocket present in Grp94. An extensive SAR for
this scaffold showed that substitutions at the 2- and 4-positions (8 and 27, respectively) manifested
excellent Grp94 affinity and selectivity. Introduction of heteroatoms into the ring also proved
beneficial, with a 2-pyridine derivative (38) exhibiting the highest Grp94 affinity (Kd = 820 nM).
Subsequent cell-based assays showed that these Grp94 inhibitors inhibit migration of the
metastatic breast cancer cell line, MDA-MB-231, as well as exhibit an anti-proliferative affect
against the multiple myeloma cell line, RPMI 8226.
Introduction
Heat shock protein 90 (Hsp90) is a molecular chaperone that plays an important role in
cellular activity by maintaining the conformational maturation of approximately 200 client
proteins. In normal cells, Hsp90 is associated with proteins responsible for trafficking, cell
signaling, protein folding, as well as the maintenance and degradation of client proteins.1,2
Hsp90 functions are modulated through three domains; the N- and C-termini and the middle
domain. The N-terminus contains an ATP-binding site which upon binding ATP closes to
induce ATP hydrolysis and provides the chaperone machinery the energy required for
protein folding. The middle domain binds the γ-phosphate of ATP and is responsible for
interactions with client proteins. The C-terminus controls Hsp90 homodimerization and also
contains a nucleotide-binding site that allosterically regulates the N-terminal domain.3–9 In
cancer cells, Hsp90 is overexpressed and involved in numerous pathways required for the
rapid growth and proliferation of cancer cells. As a consequence of its essential role in so
many processes, Hsp90 is a highly sought after therapeutic target, as disruption can
simultaneously affect multiple pathways required for cancer cell growth.10–12, 42–50
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Hsp90 N-terminal inhibition has been shown to be an effective therapeutic strategy as 17
inhibitors of the ATP-binding site have advanced to clinical trials for the treatment of
various cancers. Despite the number of N-terminal inhibitors in clinical trials, detrimental
activities that include cardiovascular, ocular, and/or hepatotoxicities, amongst others have
been observed for many of these investigational new drugs.13–15 Unfortunately, the N-
terminal ATP-binding site is >85% identical across all four Hsp90 isoforms, which includes
cytosolic Hsp90α and β, the endoplasmic reticulum-localized isoform, Grp94, and the
mitochondrial chaperone, Trap1.16 Since pan-inhibition of all Hsp90 isoforms can result in
the degradation of more than 200 Hsp90-dependent client proteins, it is likely that toxic side
effects cannot be overcome by traditional approaches that focus upon pan-Hsp90 inhibition.
Recently, it was shown that Hsp90α is the isoform responsible for maturation of the hERG
channel, and is therefore more likely responsible for the clinically observed cardiotoxicity.17
Consequently, new approaches toward Hsp90 inhibition are needed in an effort to refine the
number of Hsp90-dependent proteins as well as to escape the deleterious consequences of
pan-Hsp90 inhibition. The development of isoform-selective Hsp90 inhibitors represents an
attractive strategy for the discovery of such attributes.
Compared to cytoplasmic Hsp90 α and β, the biological role manifested by glucose
regulated protein-94 kDa (Grp94) is far less explored.16 Preliminary studies on Grp94
indicate that many of its client proteins are involved in intercellular communication and
adhesion (i.e. Toll-like receptors, myocilin, integrins, immunoglobulins).18 These properties
suggest that Grp94 inhibition may be useful for the treatment of specific disease states. For
example, since Grp94 plays an integral role in the trafficking of integrins to the cell
membrane, it represents a potential target for the development of anti-metastatic agents.19
This is further illustrated by recent work showing that Grp94 inhibition (via siRNA
knockdown) led to inhibition of cell proliferation, migration and metastasis in two
aggressive breast cancer cell lines (MDA-MB-231 cells and reactive oxygen species
resistant (ROS) MCF-7 cells).20 Grp94 has also been ascribed a role in glaucoma due to its
involvement in mutant myocilin clearance.21 In addition, Grp94 was found to be
overexpressed in multiple myeloma as a consequence of endoplasmic reticulum stress,22–24
in fact, Grp94 inhibition was shown to decrease the proliferation rate of multiple myeloma
cells.25
Despite the highly homologous nature of Hsp90 isoforms, Grp94 possesses a five-amino
acid insertion (QEDGQ) between residues 182 and 186, which translates into a small pocket
that can be accessed by Grp94 inhibitors.29 This insertion does not exist in other Hsp90
isoforms, and therefore creates a unique hydrophobic environment within the ATP-binding
domain that can lead to selective inhibition.26–29 In 2009, a novel mode of binding was
identified for the radicicol/geldanamycin chimeric inhibitor, radamide (RDA)30,31,37–40
bound to Grp94 (Figure 1). Co-crystal structures of RDA bound to both Hsp90 and Grp94
(Figure 1)30 indicated two key elements were needed to target the hydrophobic binding
pocket and to selectively bind Grp94. The first proposed modification included replacement
of the quinone ring with a phenyl substituent that interacts favorably with the hydrophobic
pocket exclusive to Grp94. The second requirement for binding to Grp94 was projection of
the phenyl group into this hydrophobic environment. Such observations led to the
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development of BnIm, which demonstrated good Grp94 inhibitory activity in a number of
assays.26 However, little effort towards the development of RDA as a Grp94 inhibitor has
been pursued, until now. Therefore, the goal of this project was to further evaluate RDA as a
Grp94 inhibitor and to establish structure-activity relationships for this class of inhibitors.
Results and Discussion
Optimization of the RDA scaffold required several modifications to access the unique
hydrophobic pocket within Grp94. The first investigation needed to determine the optimal
linker length between the amide and the aromatic ring that projects into the hydrophobic
pocket (compounds 2–5) as suggested by Figure 1. This is necessary to determine how deep
these molecules can project into the pocket and to provide a scaffold upon which
substituents can be readily incorporated for elucidation of structure-activity relationships.
Substitutions around the aryl ring would then probe for beneficial interactions with the
peptide binding pocket as outlined in Scheme 1. These observations led to the design and
synthesis of compounds that would provide an initial set of data to direct subsequent
optimization efforts. Since RDA bound to Grp94 (Scheme 1) indicated an extended π-
stacking environment with Phe199 and Tyr200, naphthyl, indole, and indoline scaffolds
were also pursued to take advantage of potential interactions. These aryl systems could then
be modified to contain additional substitutions about the ring for further access into the A
and B pockets. Due to π-π interactions with Phe199 and Tyr200, probing the electronic
nature of the aryl ring via the addition of heteroatoms that could enhance interactions was
also investigated and led to the identification of additional compounds. Lastly, since the cis-
amide conformation was found important for binding Grp94 (Figure 1), tertiary amides were
prepared to promote the cis-conformation.
Projection of the phenyl ring into the hydrophobic binding region (Scheme 1) required
optimization of the linker length between the amide and phenyl groups, leading to the
synthesis of 2–5 (Figure 2). Molecular modeling studies indicated that phenyl amide 2
would provide the ideal linker for binding Grp94. In an effort to validate this model and to
support this hypothesis, linkers between the amide and the phenyl ring were synthesized and
analyzed for inhibitory activity. In the event, TBS-protected acid 1, was coupled with the
corresponding aniline, benzylamine, phenethylamine, or phenyl hydrazine, utilizing 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) and pyridine in dichloromethane, to
generate the corresponding amides . These compounds were subsequently treated with
tetrabutylammonium fluoride (TBAF) to unmask the phenols, 2–5, in good yields. These
compounds were evaluated for their ability to bind Grp94 via a competitive binding
fluorescence polarization assay (Figure 2).32,33 As suggested by computational studies,
phenyl amide 2, was found to contain the optimal linker as compared to benzyl amide,
phenethyl amide, and hydrazine amide (3, 4, and 5, respectively). As described earlier, RDA
analogs appear to manifest π-π interactions with Phe199 and Tyr200, therefore, compound
6, containing a cyclohexyl ring in lieu of the phenyl ring, was synthesized and evaluated. As
expected, this compound demonstrated a decrease in binding affinity (compound 2 Grp94
Kd, 20.5 µM, compound 6 Grp94 Kd, 35.2 µM), which was in accord with our predictive
model that supported π-π stacking interactions between Grp94 and compound 2. These
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studies validated compound 2 as our starting point for further development and allowed
further interrogation of this scaffold.
Functionalization of phenyl amide 2 at the 2-, 3-, and 4-positions was pursued to explore the
space surrounding the phenyl ring and to identify key interactions by the inclusion of
electron donating and withdrawing groups. As seen in Scheme 1, there are two main pockets
(A and B) within the hydrophobic binding region. Molecular modeling indicated that the 2-
position of the phenyl ring is directed towards pocket A, whereas the 3- and 4-positions
point at B. Substitutions at these positions could also provide information about the potential
for π-stacking and hydrogen bonding interactions.
Functionalization of 2 at the 2-position on the phenyl ring was pursued with the goal of
projecting substituents into pocket A and/or altering the electronic nature for additional π-π
interactions. EDCI-mediated coupling with the corresponding anilines, 7a–15a, followed by
silyl-deprotection, generated amides 7–15 in good yields. Evaluation of 7–15 by the
fluorescence polarization assay demonstrated enhanced binding affinities for these
compounds (≤20% tracer bound) as compared to the unsubstituted lead compound. These
substitutions illustrated that both electronic and steric effects influence the ability of these
amides to bind Grp94, and the 2-chloro exhibited the highest affinity (8, 0.1% tracer bound).
A trend is observed in Figure 3 which suggests that substituents larger than chlorine (for
example, 2-bromo and 2-trifluoromethyl, compounds 9 and 11, respectively) exhibit a size-
dependent decrease in binding affinity. The 2-fluoro derivative, 7, also exhibited a decrease
in binding affinity, which may result from its inability to fill this hydrophobic environment.
However, this could also be a consequence of the electronic effects manifested by fluorine,
which prevents the amide bond from adopting the cis-conformation.34 Electron donating
groups, hydrogen bond acceptors and hydrogen bond donors all exhibit a decreased affinity
for binding Grp94. Ultimately, it was discovered that a chlorine atom at the 2-position
(compound 8) proved optimal for binding to pocket A.
Additional structure-activity relationships were pursued by the incorporation of substitutions
at the 3-position of the phenyl ring. As shown in Scheme 1, the 3-position of the phenyl ring
provides access to pocket B and therefore, substitutions were incorporated to elucidate the
size of this pocket, the electronic nature that can enhance π-π stacking interactions, and
potentially, hydrogen bonding interactions with Gly196. This led to the synthesis of 3-
substituted amides by an EDCI-mediated coupling of acid 1 with the corresponding anilines,
16a–24a, followed by silyl-deprotection to give the desired amides, 16–24, in good overall
yields. As seen in Figure 4, these substitutions followed a similar trend for Grp94 binding as
observed for the 2-position, as chlorine at the 3-position (17) displayed the highest binding
affinity for Grp94. In comparison, larger (compounds 18–20) and smaller (compound 16)
substituents resulted in diminished binding. In contrast to the 2-position, incorporation of a
hydroxyl or amino group at the 3-position (compounds 21 and 22, respectively) led to
increased affinity for Grp94 (potentially through a gained hydrogen bonding interaction with
Gly196). Both amino and N-acetamides manifested decreased binding affinity as compared
to the phenol, as they are known to form weaker hydrogen bonds. Ultimately, the 3-chloro
derivative proved to bind Grp94 more efficiently than the 3-phenol, indicating a preference
for hydrophobic over hydrogen bonding interactions at this location.
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The 4-position of the phenyl ring was also explored by the introduction of electron donating
and withdrawing groups. As indicated in Scheme 1, the 4-position appears optimal for
directing substituents into pocket B, however, a potential hydrogen bonding interaction with
Gly196 could also be rationalized. Similar to 3-substitutions, the 4-position was investigated
for steric constraints in pocket B, as well as elucidation of the electronic nature for π-π
interactions with Phe199 and Tyr200. Compounds 25–37 were synthesized via EDCI-
mediated coupling of TBS-acid 1 with the corresponding anilines, 25a–37a, followed by
silyl-deprotection to provide amides 25–37 in good overall yields. When evaluated for their
ability to bind Grp94, the 4-position followed a very clear SAR trend with particular
sensitivity to sterics (as shown in Figure 5). In contrast to the 2- and 3-positions, the 4-
position appears to accommodate larger functionalities, as illustrated by the inclusion of
bromine at the 4-position (compound 27), which displayed excellent affinity for Grp94. The
enhanced affinity for 27 was anticipated as the 4-bromine can project well into the
hydrophobic pocket of area B (Scheme 1). A decrease in binding affinity was observed (as
compared to 27) for both smaller substitutions (4-fluoro and 4-chloro, compounds 25 and 26
respectively) and larger substitutions (4-iodo, 4-trifluoromethyl, and 4-isopropyl,
compounds 28, 29, and 37, respectively). Similar to the trends observed for the 2- and 3-
positions, electron withdrawing groups at the 4-position also displayed higher binding
affinity than electron donating groups. A hydrogen bond donor at the 4-position also
displayed good binding affinity (4-hydroxyl, compound 32), and this affinity could be
altered by conversion to the methyl ether (34), which manifested decreased affinity.
Compound 35, containing a nitrile group at the 4-position, also displayed enhanced Grp94
binding, which may be attributed to its electron withdrawing ability as well as its ability to
serve as a hydrogen bond acceptor. As predicted by molecular modeling studies which
clearly outlined the A and B pockets as important for binding, both the 2- and 3-substituted
compounds (8 and 17, respectively) exhibited the greatest influence on Grp94 binding as
compared to the 4-substituted derivatives (27).
Preliminary molecular modeling studies (Scheme 1) indicated that one explanation for the
enhanced activity of the phenyl amide scaffold was due to its potential to π-stack with the
electron-rich rings of Phe199 and Tyr200, suggesting that π-stacking with these residues
could be enhanced by alteration of the electron density on the phenyl ring. Structure-activity
relationships at the 2-, 3-, and 4-positions supported this hypothesis as decreased electron
density (via electron withdrawing groups) led to enhanced binding. Further validation of this
hypothesis prompted the introduction of heteroatoms into the aromatic ring to enhance these
π-stacking interactions.
Investigation of the influence that electron withdrawing groups exhibit led to a series
heterocycles that exhibited decreased electron density within the aromatic ring. Sulfur
containing 5-membered heterocycles (46–48) were synthesized to represent a ring similar in
size as the corresponding 6-membered analogs (38–45), while manifesting some electron
deficiency. As described previously, these analogs were generated by an EDCI-mediated
coupling of TBS-protected acid 1 with corresponding amines 38a–48a, followed by silyl-
deprotection to afford the desired amides, 38–48. Evaluation of the pyridine analogs showed
that a nitrogen atom at the 2-position (38) resulted in the highest binding affinity, followed
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by the 3- (39) and 4-incorporation (40), respectively (as shown in Figure 6). Molecular
modeling studies suggest this trend was due at least in part by the ability of the nitrogen
atom to project towards the open channel, while simultaneously maintaining optimal
orientation for π-stacking with Phe199 and Tyr200. However, when the nitrogen was moved
to the 3-position (40), nitrogen is shifted towards the channel, resulting in less favorable π-
stacking interactions. The 4-pyridine derivative (40) demonstrated the lowest binding
affinity due to its inability to access the open channel, and instead was forced into
unfavorable interactions with the hydrophobic binding pocket of B. Pyridazine 42 was
prepared to determine whether the incorporation of 2- and 3-containing nitrogen atoms
could simultaneously exist while providing π-π interactions. Unfortunately 42 did not
improve binding affinity, suggesting that the inclusion of a nitrogen atom at the meta-
position is not favored. Subsequent analogs that contained the 2-pyridine nitrogen and other
nitrogen locations (41–45, Figure 6) were explored, but unfortunately, did not improve
affinity. In contrast, thiazole 46 and thiadiazoles 47 and 48 displayed good binding affinity
and reinforced the importance of nitrogen incorporation at the 2-position.
An understanding of this scaffold’s ability to selectively bind Grp94 required binding
affinity evaluation to another isoform, Hsp90α. As shown in Figure 8, phenyl amide 2 did
not demonstrate selectivity for Grp94 (~1:1), illustrating the need to optimize this scaffold
for greater selectivity. However, substitution at the 2-, 3-, and 4-positions on the phenyl ring
(compounds 8, 17, and 27 respectively) did enhance selectivity for Grp94. Specifically,
compound 27 showed the greatest selectivity (~27-fold at 25 µM), indicating the importance
of substituents at the 4-position for selective inhibition, while 8 and 17 manifested 8- and
25-fold selectivity, respectively. It was also observed that heterocycles 38, 46 and 47
exhibited selectivity, albeit to a lesser extent than 8, 17, and 27. In an effort to further
improve Grp94-selective binding, tertiary amides 49–53 were developed. These compounds
were designed to enhance isomerization to the cis-amide conformation, by making the cis-
conformation lower in energy, which appears preferred for Grp94-inhibition (Figure 1).
Compounds 49, 50 and 53 were prepared by an EDCI-mediated coupling of TBS-protected
acid 1 with anilines 49a, 50a, and 53a, followed by silyl-deprotection to afford the desired
amides, 49, 50, and 53. 51 and 52 required an alternative method for their preparation.
Compound 51 was generated by conversion of the benzyl-protected acid 1a to the
corresponding acid chloride, followed by coupling with aniline 51a and subsequent
debenzylation to afford desired amide 51 (Figure 7). Compound 52 was prepared by
catalyst-mediated coupling of aldehyde 1b with nitrosobenzene, followed by silyl-
deprotection to afford amide 52 (Figure 7).35 Unfortunately, compounds 49–51 and 53
exhibited little to no improvement in Grp94-selectivity (Figure 8), while simultaneously
manifesting decreased binding affinities (Figures 7 and 8). In contrast, compound 52, which
contains an N-hydroxyl, demonstrated a significant increase in selectivity, however, at the
consequence of lower affinity (Figures 7 and 8).
Further optimization of this scaffold was pursued to develop more potent and selective
Grp94 inhibitors by combining the features identified above to produce 54–65, which
contain the phenyl amide, an ortho-pyridine, a thiazole, or a thiadiazole ring along with
substitution patterns based on earlier studies (Figure 9). These compounds were also
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synthesized by the EDCI-mediated coupling of acid 1 with anilines 54a–65a. Subsequent
silyl-deprotection of the resulting amides afforded 54–65. Unfortunately, 54–58, 60, 61, and
63–65 were unable to exhibit Grp94 binding affinity similar to 8, 17, 27 or 38. Some of the
compounds (60, 61, and 63) exhibited a slight enhancement for Grp94 selectivity, but also
demonstrated lesser affinity. However, 58, 59 and 62 demonstrated a high Grp94 binding
affinity (≤1% tracer bound), while also manifesting good selectivity (4–18% tracer bound
for Hsp90α). Despite these characteristics, compounds 54–65 did not manifest greater
binding affinity or selectivity for Grp94 than previously prepared analogs.
Compounds 8, 17, 27, 38, 46 and 47 were evaluated for determination of their respective Kd
values for Grp94 binding. Kd’s were determined in a manner similar to the 25 µM
fluorescence polarization screen, wherein compounds were incubated with Grp94 and FITC-
GDA for 24 h at increasing concentrations. From the data, the Kd values for 8, 17, 27, 38,
46, and 47 were determined as shown in Table 1. In accord with earlier studies, substitutions
at the 2- and 4-positions (8 and 27, respectively) manifested better activity than the 3-
position (17). The importance of a nitrogen atom at the 2-position was also confirmed as 38
manifested the highest affinity (0.82 µM), while both 46 and 47 also displayed less affinity
(1.08 µM and 1.54 µM, respectively). Compounds 38 and 46 manifested the highest affinity
for Grp94, and therefore were used in subsequent cell-based assays.
Inhibition of Migration and Proliferation of MDA-MB-231 cells
Inhibition of Grp94 has been linked to decreased metastasis, migration and proliferation in
the highly metastatic breast cancer cell lines, MDA-MB-231 and ROS-resistant MCF-7.20
Specifically, silencing Grp94 expression caused almost complete inhibition of migration as
well as a signficant decrease in proliferation of the highly aggressive metastatic breast
cancer cell line, MDA-MB-231.20 While compounds 38 and 46 manifested modest anti-
proliferative activities against MDA-MB-231 cells (38: IC50=12 µM, 46: IC50=16 µM), they
did demonstrate potent anti-migratory properties against the same cell line. This was
determined by employing a wound healing assay where a monolayer of cells was grown in a
12-well plate format. In each well, two wounds were created in which cells can migrate and
heal the wound. Migration was recorded at 0 h, 16 h, and 24 h using a digital camera
mounted microscope. In addition, each compound was tested at 2.5 µM (Figure 10) up to 25
µM (Supporting Information, Figures S1–S2) where they demonstrated no cytotoxicity. The
results at 2.5 µM are shown in Figure 10.
Compounds 38 and 46 were evaluated in this assay as they manifested the most potent (Kd
values, Table 1) Grp94 inhibition while also manifesting good selectivity for Grp94 binding
(Figure 8). As shown in Figure 10, they inhibited cell migration consistent with Grp94
inhibition, which was also in accord with prior studies by Verrax and coworkers20, wherein
they showed that Grp94 knockdown led to migratory inhibition of MDA-MB-231 cells. The
ability of these compounds to inhibit migration mirrored the trend observed in the
fluorescence polarization assay, where compound 38 manifested a greater anti-migratory
effect than compound 46. The anti-migratory effect of these compounds was determined to
be dose-dependent (Supporting Information, Figures S1 and S2). Ultimately, the wound-
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healing assay illustrates the potential for Grp94-inhibitors to be used in the treatment of
highly metastatic breast cancers, while manifesting minimal toxicity.
Compounds 38 and 46 demonstrated the ability to bind Grp94 in MDA-MB-231 cells. The
anti-Grp94 (9G10) antibody recognizes the open conformation of Grp94, and when an
inhibitor is bound to this region, Grp94 switches to the closed conformation. Therefore, the
9G10 antibody does not recognize Grp94 bound to an inhibitor.26,37 Compounds 38 and 46
demonstrated a dose-dependent effect by inducing a conformational change in Grp94, and
thus, prevented the 9G10 antibody from recognizing and immunoprecipitating Grp94 from
MDA-MB-231 cells (as shown in Figure 11). These findings correspond well with the
observed anti-proliferative and anti-migratory concentrations, indicating these effects
parallel Grp94-inhibition.
Previous studies have shown that Grp94-inhibition decreases insulin-like growth factor-II
(IGF-II) secretion, which also plays an important role in the proliferation and migration of
certain cancers.26,51,52 Compounds 38 and 46 decreased secretion of the Grp94-dependent
client protein, IGF-II, as shown in Figure 12. The dramatic decrease in IGF-II secretion was
observed at concentrations that parallel the concentrations needed to exhibit anti-migratory
activity.
Compounds 38 and 46 also demonstrated selective Grp94-inhibition by Western blot
analysis of Hsp90 client proteins Akt and Cyclin D1 from MDA-MB-231 cell lystates
(Figure 13). Degradation of Hsp90-dependent cytosolic clients, Akt and Cyclin D1, was not
observed at a high concentration of compound 38 (60 µM), indicating other Hsp90 isoforms
were not affected at the concentration needed to exhibit anti-migratory activity (2.5–25 µM).
Compound 46 demonstrated modest client-protein degradation at 80 µM, however, this
effect was observed at concentrations significantly higher than the concentration needed for
anti-migratory activity. This finding along with the observed effects of utilizing the 9G10
antibody (Figure 11) and decreased IGF-II secretion (Figure 12) indicate these compounds
inhibit Grp94 at concentrations relevant to the observed anti-migratory activity.
Anti-proliferative effect on RPMI 8226 cells
Recently, elevated levels of Grp94 were linked to the accelerated proliferation of multiple
myeloma cells,22–24 identifying Grp94 as a potential therapeutic target for the treatment of
myeloma.25 The RPMI 8226 multiple myeloma cell line was shown to be particularly
sensitive to Grp94 inhibition, which prompted investigation of compounds 38 and 46 for
their anti-proliferative activity against this cell line.
As anticipated, the two most potent compounds for binding Grp94 (Table 1) also exhibited
potent anti-proliferative properties against the RPMI 8226 cell line (IC50 <10 µM).
Interestingly, 38 displayed a slightly lower anti-proliferative effect (9.12 µM) than 46
despite its superior binding affinity. These compounds were then evaluated for their ability
to selectively inhibit Grp94 in RPMI 8226 cells in a similar fashion seen for MDA-MB-231
cells.
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Compounds 38 and 46 did demonstrate an ability to bind Grp94 in RPMI 8226 cells in a
dose-dependent manner. This was first determined by use of the 9G10 antibody to recognize
Grp94 in immunoprecipitated RPMI8226 cell lysates treated with compounds 38 and 46
(Figure 14). These data indicate that compounds 38 and 46 bind Grp94 at concentrations
needed to inhibit the proliferation of RPMI 8226 cells.
Compounds 38 and 46 also decreased secretion of the Grp94-dependent client protein, IGF-
II; at concentrations similar to the observed anti-proliferative activity manifested by both
compounds (Figure 15). Along with the use of the 9G10 antibody (Figure 14), this data also
suggests that the observed anti-proliferative activity of compounds 38 and 46 against RPMI
8226 cells is attributed to the inhibition of Grp94 in RPMI 8226 cells.
Compounds 38 and 46 also demonstrated that their anti-proliferative activities are likely due
to selective Grp94 inhibition. This was illustrated by the inability of compound 38 to
degrade Hsp90 client-proteins Akt and cyclin D1 (Figure 16) at concentrations above and
below its respective anti-proliferative IC50 value. Compound 46 demonstrated modest
client-protein degradation at concentrations five-fold higher than its IC50, indicating a
slightly lower selectivity for Grp94. However, this data does indicate that compounds 38 and
46 inhibit Grp94 in RPMI 8226 cells, which results in their anti-proliferative activity. The
ability of this scaffold to selectively inhibit Grp94 and manifest anti-proliferative activity
against the RPMI 8226 multiple myeloma cell line demonstrates the therapeutic potential of
Grp94 inhibition for the treatment of these cancers.
Conclusion
Using the previously reported co-crystal structure of RDA bound to Grp94, a series of RDA
analogs were designed, synthesized, and evaluated for their ability to inhibit Grp94. A
comprehensive SAR study of this scaffold indicated several key features necessary for
selective inhibition of Grp94 (Figure 17). Initial optimization of the linker led to the
identification of phenyl amide, 2, manifesting the highest Grp94 affinity (blue, Figure 17).
This finding demonstrated both the importance of a short linker, as well as the presence of
an aromatic ring for π-stacking interactions. Substituents at the 2- and 4-positions (pink and
green, Figure 17) of the phenyl amide demonstrated increased Grp94 binding affinity and
selectivity, with chlorine and bromine substituents identified as optimal (Table 1,
compounds 8 and 27, respectively). Substitution at the 3-position (orange, Figure 17) also
proved important; however, both potency and selectivity were decreased relative to
substitutions at the 2- and 4-positions (Table 1, compound 17). In contrast, modifications to
the 4-position resulted in the greatest effect on selectivity, as most substituents at this
position manifested enhanced selectivity. Decreasing the electron density of the aromatic
ring via the introduction of heteroatoms (38, 46, and 47) not only increased binding affinity,
but also increased selectivity. However, this finding was specific to the incorporation of a
nitrogen atom at the 2-position (Figure 6). The 2-pyridine ring was successfully incorporated
with the 4-bromine or 3-chlorine derivative to provide potent and selective Grp94-inhibitors.
Subsequent in vitro analysis of 38 and 46 further validated the therapeutic potential for
Grp94 inhibitors as well as validated selective Grp94-inhibition. The ability of these
compounds to inhibit Grp94 was correlative with their anti-migratory activity against the
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highly metastatic breast cancer cell line, MDA-MB-231, as well as anti-proliferative activity
against the multiple myeloma cell line, RPMI 8226.
General Experimental Methods
Fluorescence Polarization
Assay buffer (25 µL, 20 mM HEPES pH 7.3, 50 mM KCl, 5 mM MgCl2, 1 mM DTT, 20
mM Na2MoO4, 0.01% NP-40, and 0.5 mg/mL BGG) containing desired compound or GDA
were plated in 96-well plates (black well, black bottom) at the indicated final concentrations
in DMSO (1% DMSO final concentration).32 Recombinant cGrp94 and FITC-GDA were
then added (10 and 6 nM, respectively). Plates were incubated with rocking for 24 h at 4°C.
Fluorescence was read using excitation and emission filters of 485 and 528 nm, respectively.
Percent FITC-GDA bound was determined by using the DMSO millipolarization unit (mP)
as the 100% bound value and the mP value of free FITC-GDA as the 0% bound value. Kd
values were calculated from separate experiments performed in triplicate using GraphPad
Prism.
Anti-proliferation Assays
RPMI 8226 and MDA-MB-231 cells were maintained in RPMI1640 (Cellgro) and DMEM
(Cellgro), respectively, supplemented with nonessential amino acids , L-glutamine (2 mM),
streptomycin (500 µg/mL), penicillin (100 units/mL) and 10% FBS. Cells were grown to
confluence in a humidified atmosphere (37°C, 5% CO2), seeded (2000/well, 100 µL) in 96-
well plates, and allowed to attach overnight. Compound at varying concentrations in DMSO
(1% DMSO final concentration) was added, and cells were returned to the incubator for 72
h. After 72 h, the number of viable cells was determined using an MTS/PMS cell
proliferation kit (Promega) per the manufacturer’s instructions. Cells incubated in 1%
DMSO were use as 100% proliferation, and values were adjusted accordingly. IC50 values
were calculated from separate experiments performed in triplicate using GraphPad Prism.
Wound-Healing Assay
Cells were grown to confluence in a humidified atmosphere (37°C, 5% CO2), seeded
(200000/well, 1 mL) in 12-well plates, and allowed to grow to a confluent monolayer (24 h)
at 37°C and 5% CO2. Each well was then scratched with a 200 µL sterile pipet tip,
photographed with an Olympus IX-71 microscope (60x objective, time=0 h), the respective
compound solutions (2.5 µL, final DMSO concentration is 0.25%) were added, and the
plates were placed back in the incubator. Cell migration was recorded after 16 and 24 h of
incubation with compound via photographs taken by the Olympus IX-71 microscope. All
experiments were run in quadruplicate on two different days.
Western Blotting
MDA-MB-231 and RPMI 8226 cells were plated in 6-well plates and treated with high and
low concentrations of compounds 38 and 46, as well as 15 µM RDC in DMSO (0.25%
DMSO final concentration), or DMSO only for 24 h. Cells were harvested in cold PBS and
lysed in mammalian protein extraction reagent (MPER, Pierce) and protease inhibitors
(Roche) on ice for 15 min. Lysates were clarified at 15,000 rpm for 15 min at 4°C. Protein
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concentrations were determined with the Pierce BCA assay kit per the manufacturer’s
instructions. Equal amounts of protein (20 µg) were electrophoresed under reducing
conditions, transferred to a PVDF membrane, and immunoblotted with the corresponding
specific antibodies. The corresponding amount of media necessary to maintain equal actin
levels was also electrophoresed under reducing conditions, transferred to a PVDF
membrane, and immunoblotted with the IGF-II antibody. Membranes were incubated with
an appropriate horseradish peroxidase-labeled secondary antibody, developed with
chemiluminescent substrate, and visualized.
Grp94 Immunoprecipitation
Detergent lysates of the indicated cells were immunoprecipitated with 9G10 monoclonal
anti-Grp94 (Enzo Life Sciences) followed by protein G-MagBeads (GenScript) as
previously described.37
Molecular Modeling
Surflex-Dock in Sybyl v8.0 was used for molecular modeling and docking studies. The co-
crystal structure of RDA bound to Grp94 was utilized for all docking experiments.30 The
docked molecules were locked into the cis-amide conformation and utilized with 10
different starting conformations while rotation of the rotatable bonds was unrestricted.
Visual interpretation and figure preparation were then carried out in Pymol.
Chemistry General
1H NMR were recorded at 400 or 500 MHz (Bruker DRX-400 Bruker with a H/C/P/F QNP
gradient probe) spectrometer and 13C NMR spectra were recorded at 125 MHz (Bruker
DRX 500 with broadband, inverse triple resonance, and high resolution magic angle
spinning, HR-MA probe spectrometer); chemical shifts are reported in δ (ppm) relative to
the internal chloroform-d (CDCl3, 7.27 ppm). FAB (HRMS) spectra were recorded with a
LCT Premier (Waters Corp., Milford, MA). The purity of all compounds was determined to
be >95% purity as determined by 1H NMR and 13C NMR spectra, unless otherwise noted.
The most active five compounds were verified for >95% purity by HPLC analyses. TLC was
performed on glass backed silica gel plates (Uniplate) with spots visualized by UV light. All
solvents were reagent grade and, when necessary, were purified and dried by standard
methods. Concentration of solutions after reactions and extractions involved the use of a
rotary evaporator operating at reduced pressure.
General Amide Formation for Compounds 2–50 and 53–65
To a solution of acid 1 (0.05 mmol), EDCI·HCl (0.12 mmol), and pyridine (0.13 mmol) in
CH2Cl2 (1 mL) was added the corresponding aniline (0.1 mmol) and stirred at room
temperature under Ar overnight. Upon complete consumption of acid 1, the solvent was
removed in vacuo and redissolved in THF (1 mL). The reaction mixture was then treated
with TBAF (0.2 mmol) and stirred for 30 min, and upon completion saturated aqueous
NH4Cl was added and extracted 3x with EtOAc. The combined organic layers were then
dried over Na2SO4, filtered, and concentrated in vacuo to give a crude oil. The residue was
purified via flash chromatography (SiO2, 49:1, CH2Cl2:MeOH) to afford the desired amide.
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15 mg, 86% yield, white solid. 1H NMR (400 MHz, CDCl3): δ 11.23 (s, 1 H), 7.53 (d, J =
7.91 Hz, 2 H), 7.34 (t, J = 7.66 Hz, 2 H), 7.12 (t, J = 7.36 Hz, 1 H), 6.59 (s, 1 H), 6.33 (s, 1
H), 3.97 (s, 3 H), 3.50 (dd, J = 5.76, 10.15 Hz, 2 H), 2.66–2.59 (m, 2 H). 13C NMR (125
MHz, CDCl3): δ = 170.43, 169.99, 162.91, 156.28, 141.66, 137.73, 129.10 (2 C), 124.40,
119.72 (2 C), 113.92, 106.81, 102.94, 52.75, 36.73, 28.81. HRMS (FAB) m/z [M+Na+] for
C17H16ClNO5Na: 372.0609, found 372.0609.
methyl 2-(3-(benzylamino)-3-oxopropyl)-3-chloro-4,6-dihydroxybenzoate (3)—
30 mg, 83% yield, white solid. 1H NMR (500 MHz, CDCl3): δ 7.32 – 7.21 (m, 5H), 6.44 (s,
1H), 4.40 (d, J = 4.7 Hz, 2H), 3.86 (s, 3H), 3.44 – 3.29 (m, 2H), 2.50 – 2.33 (m, 2H). 13C
NMR (125 MHz, CDCl3) δ 171.98, 170.68, 162.51, 157.03, 141.87, 138.12, 127.81, 127.60,
114.22, 106.34, 102.63, 52.53, 49.78, 43.73, 35.65, 28.92. HRMS (FAB) m/z [M+Na+] for
C18H18ClNO5Na: 386.0874; found, 386.0877.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(phenethylamino)propyl)benzoate
(4)—17 mg, 90% yield, white solid. 1H NMR (400 MHz, CDCl3): δ 11.29 (s, 1 H), 7.32 (dd,
J = 6.63, 8.10 Hz, 2 H), 7.26–7.23 (m, 1 H), 7.22–7.17 (m, 2 H), 6.57 (s, 1 H), 5.48 (t, J =
5.95 Hz, 1 H), 3.91 (s, 3 H), 3.56 (q, J = 6.58 Hz, 2 H), 3.40–3.34 (m, 2 H), 2.84 (t, J = 6.84
Hz, 2 H), 2.41–2.35 (m, 2 H). 13C NMR (125 MHz, CDCl3): δ 171.92, 170.64, 162.90,
156.43, 141.74, 138.72, 128.77, 128.71, 126.63, 113.90, 106.64, 102.80, 52.58, 40.63,
35.81, 35.61, 29.05. HRMS (FAB) m/z [M+Na+] for C19H20ClNO5Na: 400.0922, found
400.0931.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(2-phenylhydrazinyl)propyl)benzoate
(5)—17 mg, 94% yield, orange solid. 1H NMR (400 MHz, CD3OD, major conformer): δ
7.23–7.13 (m, 2 H), 6.83–6.74 (m, 3 H), 6.41 (s, 1 H), 3.92 (s, 3 H), 3.36–3.28 (m, 2 H),
2.59–2.53 (m, 2 H); 13C NMR (125 MHz, CD3OD, major conformer): δ 174.8, 171.6, 161.5,
159.0, 150.0, 142.1, 130.2, 130.0, 121.0, 115.0, 114.1, 113.3, 109.5, 103.2, 52.9, 34.3, 29.1.
HRMS (FAB) m/z [M+Na+] for C17H17ClN2O5Na: 387.0724; found, 387.0723.
methyl 3-chloro-2-(3-(cyclohexylamino)-3-oxopropyl)-4,6-dihydroxybenzoate
(6)—33 mg, 88% yield, white solid. 1H NMR (500 MHz, CDCl3) δ 6.41 (s, 1H), 3.89 (s,
3H), 3.68 (s, 1H), 3.40 – 3.24 (m, 2H), 2.40 – 2.26 (m, 2H), 1.91 – 1.76 (m, 2H), 1.64 (dt, J
= 13.8, 3.8 Hz, 2H), 1.61 – 1.52 (m, 1H), 1.39 – 1.25 (m, 2H), 1.07 (ddd, J = 19.2, 9.8, 3.9
Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 171.44, 170.78, 162.49, 157.48, 142.07, 114.43,
106.04, 102.51, 52.46, 49.40, 48.22, 35.90, 33.07, 28.92, 25.46, 24.83. HRMS (FAB) m/z
[M+Na+] for C17H22ClNO5Na: 378.1187; found, 378.1167.
methyl 3-fluoro-2-(3-((2-chlorophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (7)—15 mg, 81% yield, white solid. 1H NMR (500 MHz, CDCl3) δ
11.19 (s, 1H), 8.49 – 8.00 (m, 1H), 7.34 (s, 1H), 7.12 – 6.97 (m, 3H), 6.53 (s, 1H), 6.05 (s,
1H), 3.91 (s, 3H), 3.49 – 3.37 (m, 2H), 2.67 – 2.57 (m, 2H).13C NMR (125 MHz, CDCl3) δ
170.45, 169.98, 163.02, 156.23, 141.37, 124.71, 124.68, 124.37, 124.31, 121.60, 114.87,
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114.72, 113.86, 106.81, 102.99, 52.73, 36.80, 28.83. HRMS (FAB) m/z [M+Na+] for
C17H15ClFNO5Na: 390.0521; found, 390.0547.
methyl 3-chloro-2-(3-((2-chlorophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (8)—14 mg, 73% yield, white solid. 1H NMR (500 MHz, CDCl3) δ
11.22 (s, 1H), 8.36 (d, J = 8.3 Hz, 1H), 7.61 (s, 1H), 7.31 (dd, J = 8.0, 1.5 Hz, 1H), 7.26 –
7.21 (m, 1H), 7.02 – 6.97 (m, 1H), 6.53 (s, 1H), 3.91 (s, 4H), 3.54 – 3.32 (m, 2H), 2.76 –
2.47 (m, 3H).13C NMR (125 MHz, CDCl3) δ 170.49, 163.08, 156.23, 141.30, 134.49,
129.04, 127.85, 124.68, 121.47, 113.86, 106.83, 103.00, 52.75, 37.03, 28.90. HRMS (FAB)
m/z [M+Na+] for C17H15Cl2NO5Na: 406.0225; found, 406.0246.
methyl 2-(3-((2-bromophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (9)—16.3 mg, 76% yield, pale yellow solid. 1H NMR (500 MHz,
CDCl3) δ 11.25 (s, 1H), 8.49 – 7.19 (m, 7H), 6.93 (td, J = 7.7, 1.4 Hz, 1H), 6.53 (s, 1H),
6.13 (s, 1H), 3.91 (s, 3H), 3.53 – 3.36 (m, 2H), 2.64 (t, J = 8.3 Hz, 2H).13C NMR (125 MHz,
CDCl3) δ 170.54, 170.04, 163.07, 156.29, 141.26, 135.54, 132.27, 128.50, 125.26, 121.80,
113.89, 113.18, 106.80, 103.01, 52.79, 37.05, 27.08. HRMS (FAB) m/z [M+Na+] for
C17H15BrClNO5Na: 449.9720; found, 449.9767.
methyl 3-chloro-4,6-dihydroxy-2-(3-((2-iodophenyl)amino)-3-
oxopropyl)benzoate (10)—18.2 mg, 77% yield, pale yellow solid. 1H NMR (500 MHz,
CDCl3) δ 11.27 (s, 1H), 8.21 (d, J = 8.2 Hz, 1H), 7.77 – 7.23 (m, 3H), 6.82 – 6.78 (m, 1H),
6.53 (s, 1H), 6.03 (s, 1H), 3.92 (s, 3H), 3.51 – 3.37 (m, 3H), 2.72 – 2.52 (m, 3H). 13C NMR
(125 MHz, CDCl3) δ 170.58, 163.13, 156.24, 141.26, 138.84, 138.04, 129.38, 126.07,
121.88, 113.88, 106.85, 103.01, 52.84, 37.05, 28.97. HRMS (FAB) m/z [M+Na+] for
C17H15ClINO5Na: 497.9581; found, 497.9593.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-((2-
(trifluoromethyl)phenyl)amino)propyl)benzoate (11)—33 mg, 79% yield, white
amorphous solid: 1H NMR (400 MHz, CDCl3-MeOD) δ 6.87 (d, J = 1.4 Hz, 1H), 6.84 (d, J
= 1.4 Hz, 1H), 6.41 (s, 1H), 6.08 (d, J = 3.1 Hz, 1H), 5.84 (dd, J = 3.0, 1.3 Hz, 1H), 4.88 (s,
2H), 3.84 (s, 3H), 3.49 – 3.41 (m, 2H), 3.02 – 2.92 (m, 2H); 13C NMR (CDCl3+CH3OH,
125 MHz): δ 171.0, 162.2, 158.3, 153.1, 147.3, 147.1, 141.9, 126.7, 119.7, 114.9, 109.7,
106.5, 102.6, 52.6, 42.7, 30.9, 26.2. (FAB) m/z [M + H+] for C18H16ClF3NO5: 418.0669;
found, 418.0658.
methyl 3-chloro-4,6-dihydroxy-2-(3-((2-hydroxyphenyl)amino)-3-
oxopropyl)benzoate (12)—23 mg, 63% yield, white amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 9.21 (br s, 1H), 7.49 (dd, J = 8.1, 1.6 Hz, 1H), 7.03 (td, J = 7.8, 1.6 Hz,
1H), 6.91 (dd, J = 8.1, 1.5 Hz, 1H), 6.82 (td, J = 7.7, 1.5 Hz, 1H), 6.52 (s, 1H), 3.96 (s, 3H),
3.54 – 3.37 (m, 2H), 2.87 – 2.74 (m, 2H); 13C NMR (125 MHz, (CD3)2CO): δ 172.9, 171.3,
162.4, 158.7, 149.1, 142.8, 127.6, 126.5, 122.7, 120.6, 118.7, 114.9, 108.1, 103.2, 53.0,
36.3, 29.4; (FAB) m/z [M + H+] for C17H16ClNO6: 388.0563; found, 388.0563.
methyl 3-chloro-4,6-dihydroxy-2-(3-((2-methoxyphenyl)amino)-3-
oxopropyl)benzoate (13)—14.5 mg, 77% yield, white solid. 1H NMR (500 MHz,
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CDCl3) δ 11.40 (s, 1H), 8.41 (dd, J = 7.9, 1.7 Hz, 1H), 7.77 (s, 1H), 7.10 – 6.85 (m, 3H),
6.59 (s, 1H), 3.96 (s, 3H), 3.87 (s, 3H), 3.56 – 3.46 (m, 2H), 2.71 – 2.62 (m, 2H).13C NMR
(125 MHz, CD3OD) δ 173.39, 171.67, 161.61, 158.99, 151.43, 142.28, 128.21, 126.10,
123.37, 121.46, 114.98, 111.74, 109.46, 103.16, 56.19, 52.83, 37.23, 29.40. HRMS (FAB)
m/z [M+H] for C18H18ClNO6: 380.0901; found, 380.0920.
methyl 2-(3-((2-aminophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (14)—7.5 mg, 41% yield, pale yellow solid. 1H NMR (400 MHz,
CD3OD) δ 7.05 – 6.92 (m, 2H), 6.79 – 6.61 (m, 1H), 6.32 (d, J = 4.7 Hz, 1H), 3.84 (d, J =
5.2 Hz, 3H), 3.31 – 3.25 (m, 2H), 2.66 – 2.60 (m, 2H). 13C NMR (125 MHz, CD3OD) δ
173.77, 171.72, 161.58, 159.34, 143.21, 142.29, 128.24, 127.13, 125.21, 119.62, 118.61,
115.21, 109.28, 103.28, 52.91, 36.45, 29.33. HRMS (FAB) m/z [M+Na+] for
C17H17ClN2O5Na: 387.0724; found, 387.0744.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(o-tolylamino)propyl)benzoate (15)—
10 mg, 25% yield, white powder. 1H NMR (400 MHz, CDCl3): δ 11.19 (s, 1 H), 7.87 (d, J =
8.0 Hz, 1 H), 7.28–7.19 (m, 2 H), 7.19–7.07 (m, 2 H), 6.67 (bs, 1 H), 6.60 (s, 1 H), 4.00 (s, 3
H), 3.60–3.48 (m, 2 H), 2.78–2.62 (m, 2 H), 2.29 (s, 3 H); 13C NMR (125 MHz, CDCl3 and
CD3OD): δ 170.8, 170.5, 161.9, 157.8, 141.9, 135.3, 130.4, 129.5, 126.6, 125.3, 123.4,
114.6, 106.0, 102.4, 52.4, 36.3, 28.9, 17.6. HRMS (FAB) m/z [M+Na+] for
C18H18ClNO5Na: 386.0771; found, 386.0769.
methyl 3-chloro-2-(3-((3-fluorophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (16)—27 mg, 74% yield, white amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 9.38 (br s, 1H), 7.86 – 7.64 (m, 1H), 7.37 – 7.22 (m, 2H), 6.81 (ddt, J =
9.1, 6.3, 2.6 Hz, 1H), 6.51 (s, 1H), 3.95 (s, 3H), 3.57 – 3.20 (m, 2H), 2.84 – 2.52 (m,
2H); 13C NMR(125 MHz, (CD3)2CO): δ 171.3, 164.7, 162.8, 162.3, 158.6, 143.0, 142.1,
131.0, 130.9, 115.5, 110.4, 108.2, 106.9, 103.2, 52.9, 36.8, 28.8; HRMS (FAB) m/z [M +
H+] for C17H15ClFNO5: 368.0701; found, 368.0701.
methyl 3-chloro-2-(3-((3-chlorophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (17)—30 mg, 78% yield, white amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 9.33 (s, 1H), 8.06 – 7.85 (m, 1H), 7.49 (ddd, J = 8.2, 2.1, 1.0 Hz, 1H),
7.31 (t, J = 8.1 Hz, 1H), 7.08 (ddd, J = 7.9, 2.1, 0.9 Hz, 1H), 6.51 (s, 1H), 3.95 (s, 3H), 3.69
– 3.33 (m, 2H), 2.85 – 2.53 (m, 2H); 13C NMR(125MHz. (CD3)2CO): δ 171.3, 171.3, 162.3,
158.6, 143.0, 141.8, 134.7, 131.0, 123.8, 119.8, 118.1, 114.8, 108.2, 103.2, 52.9, 36.8, 28.8;
HRMS (FAB) m/z [M – H−] for C17H14Cl2NO5: 382.0249; found, 382.0237.
methyl 2-(3-((3-bromophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (18)—27 mg, 74% yield, white amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 9.32 (s, 1H), 8.10 (q, J = 1.6 Hz, 1H), 7.66 – 7.46 (m, 1H), 7.38 – 7.15
(m, 2H), 6.51 (s, 1H), 3.95 (s, 3H), 3.60 – 3.33 (m, 2H), 2.73 – 2.61 (m, 2H). 13C NMR (125
MHz, (CD3)2CO) δ 171.32, 171.26, 158.63, 142.99, 141.93, 131.31, 126.77, 122.77, 122.70,
122.62, 118.63, 118.54, 114.81, 108.21, 103.18, 52.93, 36.81, 36.76, 28.84; HRMS (FAB)
m/z [M + Na+] for C17H15ClBrNO5Na: 449.9720; found, 449.9720.
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(trifluoromethyl)phenyl)amino)propyl)benzoate (19)—34 mg, 81% yield, white
amorphous solid: 1H NMR (400 MHz, CDCl3) δ 7.85 (s, 1H), 7.77 – 7.65 (m, 1H), 7.39 (t, J
= 7.9 Hz, 1H), 7.32 – 7.28 (m, 1H), 6.41 (d, J = 0.7 Hz, 1H), 5.27 (d, J = 0.7 Hz, 1H), 3.91
(d, J = 0.7 Hz, 3H), 3.50 – 3.39 (m, 2H), 2.67 – 2.45 (m, 2H); 13C NMR ( 125 MHz,
CDCl3): δ 170.7, 161.8, 158.0, 147.6, 141.6, 136.8, 136.5, 129.4, 126.4, 126.0, 125.1, 124.5,
120.1, 106.0, 102.4, 52.3, 30.7, 26.1; HRMS (FAB) m/z [M + H+] for C18H16ClF3NO5:
418.0669; found, 418.0661.
methyl 2-(3-([1,1’-biphenyl]-3-ylamino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (20)—35 mg, 72% yield, white amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 8.10 – 8.01 (m, 1H), 7.66 (tdd, J = 6.3, 2.1, 1.0 Hz, 3H), 7.52 – 7.44 (m,
2H), 7.44 – 7.33 (m, 3H), 6.52 (s, 1H), 3.97 (s, 3H), 3.63 – 3.36 (m, 2H), 2.73 – 2.56 (m,
2H); 13C NMR(125 MHz, (CD3)2CO): δ 143.2, 130.1, 129.7, 128.3, 127.7, 122.6, 118.9,
118.5, 103.1, 52.9, 36.8, 29.0; . HRMS (FAB) m/z [M +Na+] for C23H20ClNO5Na:
448.0928; found, 448.0927.
methyl 3-chloro-4,6-dihydroxy-2-(3-((3-hydroxyphenyl)amino)-3-
oxopropyl)benzoate (21)—16 mg, 88% yield, off-white solid. . 1H NMR (400 MHz,
CD3OD): δ 7.16 (t, J = 2.27 Hz, 1 H), 7.06 (td, J = 2.36, 8.01 Hz, 1 H), 6.92 (dd, J = 2.70,
7.62 Hz, 1 H), 6.50 (dd, J = 2.47, 8.35 Hz, 1 H), 6.37 (s, 1 H), 3.86 (s, 3 H), 3.91 (s, 3 H),
3.32–3.25 (m, 2 H), 2.60 (ddt, J = 3.13, 7.38 Hz, 10.18, 2 H). 13C NMR (125 MHz,
CD3OD): δ 173.26, 171.66, 161.48, 158.88, 142.34, 140.93, 130.50, 114.95, 114.93, 112.36,
112.09, 109.54, 108.40, 103.14, 52.87, 37.06, 29.09. HRMS (FAB) m/z [M+Na+] for
C17H16ClNO6Na: 388.0558, found 388.0555.
methyl 3-chloro-4,6-dihydroxy-2-(3-((3-methoxyphenyl)amino)-3-
oxopropyl)benzoate (22)—14.6 mg, 76% yield, white solid. 1H NMR (500 MHz,
CDCl3) δ 11.15 (s, 1H), 7.30 – 7.11 (m, 3H), 6.92 – 6.58 (m, 2H), 6.52 (s, 1H), 6.25 (s, 1H),
3.90 (s, 3H), 3.75 (s, 3H), 3.46 – 3.37 (m, 2H), 2.58 – 2.51 (m, 2H).13C NMR (126 MHz,
CDCl3) δ 170.82, 170.71, 162.10, 160.03, 157.67, 142.01, 139.24, 129.61, 114.59, 111.83,
109.92, 106.09, 105.39, 102.47, 55.27, 52.54, 36.41, 28.58. HRMS (FAB) m/z [M+Na+] for
C18H18ClNO6: 402.0720; found, 402.0722.
methyl 2-(3-((3-aminophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (23)—9 mg, 49% yield, pale yellow solid. 1H NMR (400 MHz,
CDCl3) δ 7.12 – 7.05 (m, 1H), 7.01 (t, J = 8.0 Hz, 1H), 6.68 (dd, J = 7.8, 2.1 Hz, 1H), 6.44 –
6.26 (m, 2H), 3.87 (s, 3H), 3.38 (t, J = 8.4 Hz, 2H), 2.61 – 2.47 (m, 2H). 13C NMR (125
MHz, CDCl3) δ 170.50, 162.27, 157.40, 146.36, 141.98, 129.72, 114.46, 111.35, 110.11,
106.84, 106.20, 102.55, 52.57, 36.57, 29.69, 28.69. HRMS (FAB) m/z [M+Na+] for
C17H17ClN2O5Na: 387.0724; found, 387.0736.
methyl 2-(3-((3-acetamidophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (24)—18 mg, 89% yield white solid. 1H NMR (400 MHz, CD3OD):
δ 7.86 (t, J = 1.91 Hz, 1 H), 7.34–7.21 (m, 3 H), 6.40 (s, 1 H), 3.91 (s, 3 H), 3.36–3.32 (m, 2
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H), 2.69–2.62 (m, 2 H), 2.12 (d, J = 1.77 Hz, 3 H). 13C NMR (125 MHz, CD3OD): δ
173.33, 171.69, 171.65, 161.43, 159.00, 142.26, 140.37, 140.33, 130.02, 116.94, 116.83,
114.97, 113.06, 109.58, 103.15, 52.84, 37.01, 29.04, 23.81. HRMS (FAB) m/z [M+Na+] for
C19H19ClN2O6Na: 428.0829, found 429.0824.
methyl 3-chloro-2-(3-((4-fluorophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (25)—14.5 mg, 80% yield, white solid. 1H NMR (500 MHz, CDCl3)
δ 11.28 (s, 1H), 7.89 (s, 1H), 7.50 (ddd, J = 9.4, 4.8, 2.4 Hz, 2H), 7.02 (t, J = 8.7 Hz, 2H),
6.50 (s, 1H), 3.96 (s, 3H), 3.52 – 3.44 (m, 2H), 2.65 – 2.56 (m, 2H). 13C NMR (125 MHz,
CDCl3) δ 170.34, 169.85, 162.91, 160.34, 156.21, 141.58, 121.57, 121.50, 115.82, 115.64,
113.88, 106.86, 102.98, 52.73, 36.57, 28.79.HRMS (FAB) m/z [M+Na+] for
C17H15ClFNO5Na: 390.0521; found, 390.0553.
methyl 3-chloro-2-(3-((4-chlorophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (26)—13.8 mg, 72% yield, white solid. 1H NMR (500 MHz, CDCl3)
δ 11.16 (s, 1H), 7.52 – 7.45 (m, 2H), 7.32 – 7.28 (m, 2H), 6.60 (s, 1H), 6.14 (s, 1H), 3.97 (s,
3H), 3.55 – 3.45 (m, 2H), 2.65 – 2.59 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 170.45,
170.35, 162.39, 157.07, 141.80, 136.48, 129.09, 128.99, 120.94, 120.84, 114.29, 106.38,
102.70, 52.62, 36.48, 28.64.HRMS (FAB) m/z [M+Na+] for C17H15Cl2NO5Na: 406.0225;
found, 406.0234.
methyl 2-(3-((4-bromophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (27)—15 mg, 70% yield, white solid. 1H NMR (500 MHz, CDCl3) δ
7.38 (s, 4H), 6.49 (s, 1H), 3.90 (s, 3H), 3.45 – 3.39 (m, 2H), 2.58 – 2.52 (m, 2H). 13C NMR
(125 MHz, CDCl3) δ 170.27, 169.88, 162.91, 156.18, 141.50, 136.83, 132.05, 121.18,
116.89, 113.864, 106.87, 103.01, 52.74, 36.71, 28.71.HRMS (FAB) m/z [M+Na+] for
C17H15BrClNO5Na: 449.9720; found, 449.9740.
methyl 3-chloro-4,6-dihydroxy-2-(3-((4-iodophenyl)amino)-3-
oxopropyl)benzoate (28)—22 mg, 76% yield, white solid. 1H NMR (500 MHz, CDCl3
and CD3OD) δ 7.55 (dd, 2H), 7.28 (dd, 2H), 6.43 (s, 1H), 3.89 (s, 3H), 3.41 – 3.39 (m, 2H),
2.56 – 2.53 (m, 2H). 13C NMR (125 MHz, CDCl3 and CD3OD) δ 169.93, 162.88, 156.22,
149.99, 141.51, 137.99, 136.22, 129.72, 128.84, 126.65, 126.34, 121.46, 103.01, 52.74,
36.74, 28.69. HRMS (FAB) m/z [M + Na+] for C17H15ClINO5Na: 497.9683; found,
497.9656.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-((4-
(trifluoromethyl)phenyl)amino)propyl)benzoate (29)—31 mg, 74% yield, white
amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 8.13 – 7.78 (m, 2H), 7.65 (dd, J = 8.8,
2.5 Hz, 2H), 6.51 (t, J = 1.7 Hz, 1H), 3.95 (t, J = 1.8 Hz, 3H), 3.44 (ddt, J = 10.2, 6.1, 1.8
Hz, 2H), 2.72 (ddt, J = 10.2, 6.3, 1.8 Hz, 2H); 13C NMR (125 MHz, (CD3)2CO) δ (171.5,
171.4, 171.3, 162.2, 158.6, 142.9, 126.9, 126.9, 126.8, 126.8, 119.8, 119.8, 114.8, 108.2,
103.2, 52.9, 36.8, 28.8. HRMS (FAB) m/z [M + H+] for C18H16ClF3NO5: 418.0669; found,
418.0669.
Muth et al. Page 16























dihydroxybenzoate (30)—12.5 mg, 60% yield, white solid. 1H NMR (400 MHz, CDCl3)
δ 7.57 – 7.48 (m, 6H), 7.41 – 7.23 (m, 3H), 7.15 (d, J = 5.6 Hz, 1H), 6.54 (s, 1H), 6.02 (s,
1H), 3.92 (s, 3H), 3.49 – 3.41 (m, 2H), 2.62 – 2.55 (m, 2H). 13C NMR (125 MHz, CDCl3) δ
170.41, 169.88, 162.96, 156.19, 141.64, 140.41, 137.25, 128.81, 127.70, 127.17, 126.84,
119.96, 113.88, 106.87, 102.96, 52.75, 36.75, 28.82. HRMS (FAB) m/z [M+Na+] for
C23H20ClNO5Na: 448.0928; found, 448.0946.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(p-tolylamino)propyl)benzoate (31)—
14 mg, 76% yield, white solid. 1H NMR (500 MHz, CD3OD) δ 7.32 (dd, J = 8.5, 2.0 Hz,
2H), 7.08 – 7.02 (m, 2H), 6.47 (s, 1H), 3.88 (s, 3H), 3.45 – 3.37 (m, 2H), 2.56 – 2.49 (m,
2H), 2.24 (s, 3H). 13C NMR (125 MHz, CD3OD) δ 168.00, 167.60, 167.51, 154.20, 139.34,
132.64, 131.47, 131.44, 127.00, 117.33, 117.21, 111.59, 104.03, 100.23, 50.14, 34.05,
26.29, 18.34.HRMS (FAB) m/z [M+Na+] for C18H18ClNO5Na: 386.0771; found, 386.1007.
methyl 3-chloro-4,6-dihydroxy-2-(3-((4-hydroxyphenyl)amino)-3-
oxopropyl)benzoate (32)—8.8 mg, 48% yield, white solid. 1H NMR (500 MHz,
CD3OD) δ 7.36 – 7.27 (m, 2H), 6.74 – 6.63 (m, 2H), 6.38 (s, 1H), 3.88 (s, 3H), 3.30–3.28
(m, 2H), 2.64 – 2.55 (m, 2H). 13C NMR (125 MHz, CD3OD) δ 172.98, 171.64, 161.37,
158.85, 155.34, 142.31, 131.72, 123.38, 116.18, 114.89, 109.69, 103.11, 52.84, 36.88,
29.19.HRMS (FAB) m/z [M+Na+] for C17H16ClNO6Na: 388.0564; found, 388.0556.
methyl 3-chloro-4,6-dihydroxy-2-(3-((4-methoxyphenyl)amino)-3-
oxopropyl)benzoate (33)—32 mg, 73% yield, white powder. 1H NMR (500 MHz,
CD3OD): δ 7.42–7.37 (m, 2 H), 6.84–6.79 (m, 2 H), 6.41 (s, 1 H), 3.90 (s, 3 H), 3.75 (s, 3
H), 3.45–3.39 (m, 2 H), 2.58–2.52 (m, 2 H). 13C NMR (125 MHz, CD3OD): δ 170.74,
170.72, 161.9, 157.8, 156.1, 142.0, 131.1, 121.6, 114.6, 114.0, 106.0, 102.3, 55.4, 52.4,
36.1, 28.6. HRMS (FAB) m/z [M+Na+] for C18H18ClNO6Na: 402.0720; found, 402.0725.
methyl 2-(3-((4-aminophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (34)—8 mg, 33% yield, dark brown solid. 1H NMR (400 MHz,
CD3OD) δ 7.45 – 7.27 (m, 2H), 6.90 – 6.74 (m, 2H), 6.50 (s, 1H), 4.00 (s, 3H), 3.41 (dt, J =
3.2, 1.7 Hz, 13H), 2.77 – 2.65 (m, 2H). 13C NMR (125 MHz, CDCl3 and CD3OD) δ 170.59,
169.91, 162.49, 156.88, 143.10, 141.99, 129.23, 121.91, 115.51, 106.47, 102.65, 52.63,
49.80, 36.43, 29.70, 28.90. HRMS (FAB) m/z [M+Na+] for C17H17ClN2O5Na: 387.0826;
found, 387.0836.
methyl 3-chloro-2-(3-((4-cyanophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (35)—13.6 mg, 72% yield, white solid. 1H NMR (500 MHz, CDCl3)
δ 7.71 – 7.60 (m, 4H), 6.56 (s, 1H), 3.98 (s, 3H), 3.53 – 3.46 (m, 2H), 2.70 – 2.64 (m,
2H). 13C NMR (125 MHz, CDCl3) δ 170.97, 170.41, 162.19, 157.38, 142.28, 141.72,
133.26, 119.32, 118.94, 114.44, 106.70, 106.26, 102.66, 52.59, 36.46, 28.41.HRMS (FAB)
m/z [M+H] for C18H15ClN2O5: 375.0748; found, 375.2276.
methyl 3-chloro-2-(3-((4-ethynylphenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (36)—18 mg, 95% yield, off-white solid. 1H NMR (400 MHz,
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CDCl3): δ 7.51–7.46 (m, 2 H), 7.39–7.34 (m, 2 H), 6.38 (s, 1 H), 3.87 (s, 3 H), 3.48–3.32
(m, 5 H), 3.01 (s, 1 H), 2.60–2.53 (m, 2 H); 13C NMR (125 MHz, CDCl3 and CD3OD): δ
171.2, 170.7, 161.8, 157.8, 141.9, 138.7, 132.7, 119.2, 117.1, 114.6, 106.0, 102.3, 83.3,
76.5, 52.3, 36.0, 28.3. HRMS (FAB) m/z [M+Na+] for C19H16ClNO5Na: 396.0615; found,
396.0608.
methyl 3-chloro-4,6-dihydroxy-2-(3-((4-isopropylphenyl)amino)-3-
oxopropyl)benzoate (37)—26 mg, 87% yield, white solid. 1H NMR (500 MHz,
(CD3)2CO) δ 9.13 (s, 1H), 7.74 – 7.52 (m, 2H), 7.27 – 7.13 (m, 2H), 6.54 (t, J = 1.5 Hz,
1H), 4.08 – 3.89 (m, 3H), 3.54 – 3.36 (m, 2H), 2.90 (td, J = 7.0, 2.1 Hz, 1H), 2.69 (ddt, J =
8.1, 6.5, 1.6 Hz, 2H), 2.15 – 2.11 (m, 1H), 1.25 (dt, J = 6.9, 1.4 Hz, 7H). 13C NMR (125
MHz, (CD3)2CO) δ 171.36, 170.68, 162.29, 158.56, 144.45, 143.28, 138.23, 138.15, 127.23,
120.07, 114.76, 108.22, 103.09, 52.91, 36.73, 34.28, 29.03, 24.41. HRMS (FAB) m/z [M
+Na+] for C20H22ClNO5Na: 414.1187; found, 414.1165.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyridin-2-ylamino)propyl)benzoate
(38)—1H NMR (500 MHz, (CD3)2CO) δ 8.39 – 8.07 (m, 2H), 7.80 (dd, J = 8.7, 7.4, 1.8 Hz,
1H), 7.10 (dd, J = 7.3, 4.8, 1.1 Hz, 1H), 6.55 (s, 1H), 3.99 (s, 3H), 3.57 – 3.42 (m, 2H), 2.98
– 2.77 (m, 2H). 13C NMR (125 MHz, (CD3)2CO) δ 171.60, 162.34, 158.67, 153.19, 148.85,
143.11, 138.72, 120.02, 114.86, 114.29, 108.11, 103.12, 52.92, 36.62, 28.77. HRMS (FAB)
m/z [M+Na+] for C16H15ClN2O5Na: 373.0669; found, 373.0630.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyridin-3-ylamino)propyl)benzoate
(39)—23 mg, 65% yield, white amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 8.80
(dd, J = 4.7, 1.5 Hz, 1H), 8.35 (dd, J = 9.0, 1.5 Hz, 1H), 7.51 (dd, J = 9.0, 4.7 Hz, 1H), 6.40
(s, 1H), 3.82 (s, 3H), 3.48 – 3.21 (m, 2H), 2.80 – 2.75 (m, 2H); 13C NMR(125 MHz,
(CD3)2CO): δ 158.6, 145.2, 143.0, 141.9, 126.7, 124.2, 103.1, 52.9, 36.7, 36.6, 28.8; HRMS
(FAB) m/z [M +H+] for C16H6ClN2O5: 351.0748; found, 351.0755.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyridin-4-ylamino)propyl)benzoate
(40)—10 mg, 51% yield, white solid. 1H NMR (500 MHz, (CD3)2CO and CD3OD) δ 9.55
(s, 1H), 8.53 – 8.40 (m, 2H), 7.73 – 7.61 (m, 2H), 6.52 (s, 1H), 3.95 (s, 3H), 3.52 – 3.40 (m,
2H), 2.75 – 2.71 (m, 2H). 13C NMR (125 MHz, (CD3)2CO) δ 172.20, 171.54, 165.56,
162.82, 151.33 (2C), 146.82, 142.44, 113.98 (2C), 103.33, 54.98, 52.68, 36.96, 28.73.
HRMS (FAB) m/z [M+Na+] for C16H15ClN2O5Na: 373.0669; found, 373.0695.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyrazin-2-ylamino)propyl)benzoate
(41)—9 mg, 26% yield, white powder. 1H NMR (400 MHz, CDCl3 and CD3OD): δ 11.22
(s, 1 H), 9.58 (s, 1 H), 8.38–8.35 (m, 1 H), 8.27–8.23 (m, 1 H), 8.02 (bs, 1 H), 6.58 (s, 1 H),
3.98 (s, 3 H), 3.55–3.48 (m, 2 H), 2.76–2.69 (m, 2 H); 13C NMR (125 MHz, CDCl3 and
CD3OD): δ 171.5, 170.6, 161.7, 158.0, 148.5, 142.2, 141.3, 139.3, 136.7, 114.6, 105.9,
102.3, 52.3, 35.7, 27.9. HRMS (FAB) m/z [M+Na+] for C15H14ClN3O5Na: 374.0520;
found, 374.0524.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyridazin-3-
ylamino)propyl)benzoate (42)—26 mg, yield 74%, white amorphous solid: 1H NMR
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(500 MHz, (CD3)2CO) δ 10.04 (s, 1H), 8.92 (dd, J = 4.7, 1.5 Hz, 1H), 8.47 (dd, J = 9.0, 1.5
Hz, 1H), 7.63 (dd, J = 9.0, 4.7 Hz, 1H), 6.52 (s, 1H), 3.94 (s, 3H), 3.54 – 3.38 (m, 2H), 2.99
– 2.84 (m, 2H); 13C NMR (125 MHz, (CD3)2CO) δ 158.78, 149.10, 142.85, 128.79, 118.60,
118.54, 103.20, 52.93, 36.60, 28.60; HRMS (FAB) m/z [M +Na+] for C15H14ClN3O5Na:
374.0520; found, 374.0534.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyrimidin-5-
ylamino)propyl)benzoate (43)—23 mg, 66% yield, white amorphous solid: 1H NMR
(400 MHz, CDCl3-MeOD) δ 9.01 (s, 2H), 8.84 (s, 1H), 6.42 (s, 1H), 3.91 (s, 3H), 3.59 –
3.36 (m, 2H), 2.70 – 2.51 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ 172.1, 170.9, 162.0,
158.1, 152.9, 147.6 (2), 141.8, 114.8 (2), 106.2, 102.6, 52.6, 35.7, 28.2; (FAB) m/z [M + H+]
for C15H15ClN3O5: 352.0712; found, 352.0712.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(pyrimidin-2-
ylamino)propyl)benzoate (44)—21 mg, yield 60%, white amorphous solid: 1H NMR
(500 MHz, (CD3)2CO) δ 9.04 (d, J = 1.3 Hz, 2H), 8.83 (s, 1H), 6.51 (s, 1H), 3.94 (s, 3H),
3.57 – 3.31 (m, 2H), 2.82 – 2.69 (m, 2H); 13C NMR(125 MHz, (CD3)2CO): δ 171.7, 171.2,
158.6, 154.2, 148.0, 147.9, 142.7, 135.6, 135.5, 114.8, 108.3, 103.2, 52.9, 36.4, 28.7; HRMS
(FAB) m/z [M + Na+] for C15H14ClN3O5Na: 374.0520; found, 374.0527.
methyl 2-(3-((1,2,4-triazin-5-yl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (45)—8.7 mg, 12% yield, yellow powder. 1H NMR (500 MHz,
CDCl3 and CD3OD): δ 8.89 (d, J = 2.5 Hz, 1 H), 8.47 (d, J = 2.5 Hz, 1 H), 6.37 (s, 1 H),
3.80 (s, 3 H), 3.45–3.38 (m, 2 H), 2.89–2.80 (m, 2 H). 13C NMR (125 MHz, CDCl3 and
CD3OD): δ 171.8, 170.7, 161.8, 158.8, 157.9, 149.7, 145.1, 141.5, 114.6, 105.9, 102.3, 52.3,
36.2, 27.6. HRMS (FAB) m/z [M+Na+] for C14H13ClN4O5Na: 375.0472; found, 375.0468.
methyl 3-chloro-4,6-dihydroxy-2-(3-oxo-3-(thiazol-2-ylamino)propyl)benzoate
(46)—30 mg, 84% yield, white amorphous solid: 1H NMR (500 MHz, (CD3)2CO) δ 7.40 (d,
J = 3.6 Hz, 1H), 7.11 (d, J = 3.6 Hz, 1H), 6.52 (s, 1H), 3.94 (s, 3H), 3.57 – 3.34 (m, 2H),
2.98 – 2.78 (m, 2H); 13C NMR ((CD3)2CO, 125 MHz) δ 171.3, 170.7, 162.4, 158.9, 158.7 ,
142.7, 138.5, 114.9, 113.9, 108.2, 103.3, 53.0, 35.4, 28.6. (FAB) m/z [M + H+] calcd for
C14H14ClN2O5S: 357.0312; found, 357.0323.
methyl 2-(3-((1,3,4-thiadiazol-2-yl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (47)—28 mg, 78% yield, white amorphous solid: 1H NMR (500
MHz, CDCl3-MeOD,) δ 8.79 (d, J = 0.9 Hz, 1H), 6.44 (d, J = 0.9 Hz, 1H), 3.89 (d, J = 0.9
Hz, 3H), 3.62 – 3.30 (m, 2H), 2.93 – 2.40 (m, 4H); 13C NMR(CDCl3-MeOD, 125 MHz):
171.0, 170.9, 162.3, 159.5, 158.1, 148.0, 141.3, 114.9, 106.1, 102.8, 52.6, 34.9, 28.0. (FAB)
m/z [M + Na+] for C13H12ClN3O5SNa: 380.0084; found, 380.0090.
methyl 2-(3-((1,2,4-thiadiazol-5-yl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (48)—19 mg, 53% yield, white amorphous solid: 1H NMR (400
MHz, CDCl3-MeOD) δ 8.19 (s, 1H), 7.72 (s, 1H), 6.36 (s, 1H), 3.83 (s, 3H), 3.50 – 3.32 (m,
2H), 2.91 – 2.69 (m, 2H); 13C NMR (CDCl3-MeOD, 125 MHz): δ 179.3, 176.3, 174.5,
Muth et al. Page 19






















163.0, 162.2.161.6, 144.8, 118.6, 110.2, 106.4, 56.3, 38.1, 33.5. (FAB) m/z [M + Na+] for
C13H12ClN3O5SNa: 380.0084; found, 380.0078.
methyl 3-chloro-4,6-dihydroxy-2-(3-(methyl(phenyl)amino)-3-
oxopropyl)benzoate (49)—28 mg, 77% yield, white amorphous solid: 1H NMR (400
MHz, CDCl3-MeOD) δ 7.34 (dd, J = 8.4, 6.8 Hz, 2H), 7.31 – 7.23 (m, 2H), 7.15 – 7.08 (m,
2H), 6.33 (s, 1H), 3.87 (s, 3H), 3.25 (d, J = 7.5 Hz, 5H), 2.35 – 2.27 (m, 2H); 13C NMR
(CDCl3-CH3OH, 125 MHz) δ 172.9, 171.0, 162.1, 157.9, 143.7, 142.3, 130.0 (2), 128.1,
127.2 (2), 114.8, 106.0, 102.3, 52.4, 37.6, 33.4, 28.9; (FAB) m/z [M + H+]for
C18H19ClNO5: 364.0952; found, 364.0943.
methyl 3-chloro-2-(3-(ethyl(phenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (50)—30 mg, 79% yield, white amorphous solid: 1H NMR (500
MHz, CDCl3-MeOD) δ 7.34 (t, J = 7.7 Hz, 2H), 7.31 – 7.24 (m, 2H), 7.06 (dd, J = 7.3, 1.7
Hz, 2H), 6.33 (d, J = 4.0 Hz, 1H), 3.87 (d, J = 3.9 Hz, 3H), 3.70 (q, J = 7.1 Hz, 3H), 3.27 –
3.19 (m, 2H), 2.34 – 2.16 (m, 2H), 1.07 (td, J = 7.2, 3.4 Hz, 3H); 13C NMR (CDCl3-MeOD,
125 MHz) δ 172.3, 171.0, 162.0, 157.9, 142.3, 141.9, 129.9 (2), 128.3 (2), 128.2, 114.7,
106.1, 102.2, 52.4, 44.3, 33.7, 28.8, 13.0; (FAB) m/z [M + H+] for C19H21ClNO5: 378.1108;
found, 378.1108.
methyl 3-chloro-4,6-dihydroxy-2-(3-(isopropyl(phenyl)amino)-3-
oxopropyl)benzoate (51)—A solution of benzyl protected acid 1a (100 mg, 0.22 mmol)
in dry CH2Cl2 was treated with oxalyl chloride (23 µL, 0.33 mmol) under Ar atmosphere
and then stirred at room temperature for 2 h. The solvent was then removed in vacuo and the
residue was placed under high vacuum for 30 min to remove any unreacted oxalyl chloride.
The residue was then redissolved in dry CH2Cl2 (3 mL), cooled to 0oC, and was treated
sequentially with diisopropylethyl amine (57 µL, 0.33 mmol) and N-isopropylaniline (72µL,
0.33 mmol). The resulting mixture was stirred at room temperature overnight under Ar. The
solvent was removed in vacuo and the residue was passed through a short pad of silica (1:1,
EtOAc:Hexanes) and was concentrated to afford the amide crude product, which was
dissolved in MeOH (5 mL) and treated with Pd/C (10 mol%, 23 mg). The resulting
suspension was charged with a hydrogen balloon and stirred under H2 at room temperature.
When debenzylation was found to be complete, the mixture was filtered through celite,
concentrated, and purified on silica gel chromatography (1:1, EtOAc:Hexanes) to afford
compound 51 (30 mg, 35% yield over 2 steps) as a white solid. 1H NMR (400 MHz,
CDCl3): δ 7.45–7.27 (m, 13 H), 7.06–7.12 (m, 2 H), 6.41 (s, 1 H), 5.07 (hept, J = 6.8 Hz, 1
H), 5.04 (s, 2 H), 4.98 (s, 2 H), 3.88 (s, 3 H), 3.03–2.93 (m, 2 H), 2.30–2.21 (m, 2 H), 1.08
(d, J = 6.8 Hz, 6 H). 13C NMR (125 MHz, CDCl3): δ 171.1, 167.5, 155.4, 154.5, 138.6,
138.3, 136.2, 135.9, 130.3, 129.2, 128.6, 128.5, 128.1, 127.9, 126.9, 126.8, 118.4, 115.5,
98.2, 70.9, 70.8, 52.4, 45.8, 34.4, 27.9, 21.0. HRMS (FAB) m/z [M+Na+] for
C20H22ClNO5Na: 414.1084; found, 414.1076.
methyl 3-chloro-4,6-dihydroxy-2-(3-(hydroxy(phenyl)amino)-3-
oxopropyl)benzoate (52)—A round bottom flask was charged with aldehyde 1b (100
mg, 0.2 mmol), nitrosobenzene (22 mg, 0.2 mmol), and 6,7-Dihydro-2-
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pentafluorophenyl-5H–pyrrolo[2,1-c]-1,2,4-trazolium tetrafluoroborate (catalyst, 7 mg, 0.02
mmol) and purged with argon. The mixture was then dissolved in CH2Cl2 (1.5 mL) followed
by addition of DBU (3µL, 0.02 mmol) and stirred at room termperature for 30 min. Upon
completion, the solvent removed in vacuo. The resulting residue was dissolved in THF (2
mL) and treated with TBAF (0.5 mL of 1M solution). After complete silyl-deprotection,
saturated aqueous NH4Cl was added and extracted 3x with EtOAc (15 mL). The crude
material was purified via flash chromatography (SiO2, 2:3 EtOAc:Hexanes) to yield 52 as an
off white solid (16 mg, 94%). 1H NMR (400 MHz, CDCl3): δ 11.30 (s, 1 H), 7.45–7.32 (m,
5 H), 6.52 (s, 1 H), 3.88 (s, 3 H), 3.42–3.36 (m, 2 H), 2.73–2.48 (m, 2 H). 13C NMR (125
MHz, CDCl3): δ 170.74, 163.10, 156.32 (2 C), 141.18, 137.80, 129.57, 126.54, 119.88,
114.00, 106.92, 103.03 (2 C), 52.71, 31.51, 28.84, 28.82. HRMS (FAB) m/z [M+Li+] for
C17H16ClNO6Li: 372.0826, found 372.0823.
methyl 3-chloro-4,6-dihydroxy-2-(3-(indolin-1-yl)-3-oxopropyl)benzoate (53)—
15 mg, 25% yield, white solid. 1H NMR (400 MHz, CDCl3): δ 1H NMR (400 MHz, CDCl3
and CD3OD) δ 8.19 (d, J = 8.0 Hz, 1H), 7.24 – 7.10 (m, 2H), 6.99 (d, J = 1.2 Hz, 1H), 6.42
(d, J = 1.5 Hz, 1H), 4.00 (dd, J = 9.1, 7.8 Hz, 2H), 3.88 (d, J = 2.8 Hz, 3H), 3.52 – 3.40 (m,
2H), 3.16 (t, J = 8.4 Hz, 2H), 2.75 – 2.60 (m, 2H). 13C NMR (125 MHz, CDCl3 and
CD3OD) δ 170.88, 170.71, 162.06, 157.89, 142.74, 142.21, 131.21, 127.50, 124.61, 123.81,
116.90, 114.64, 106.04, 102.42, 102.35, 52.51, 50.07, 49.72, 49.55, 49.38, 49.21, 49.03,
48.86, 48.69, 47.97, 35.08, 27.95, 27.84. HRMS (FAB) m/z [M+Na+] for C19H18ClNO5Na:
398.0771; found, 398.0773.
methyl 3-chloro-2-(3-((2,4-dibromophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (54)—21 mg, 83%, white solid. 1H NMR (500 MHz, CDCl3 and
CD3OD) δ 8.22 (d, J = 8.9 Hz, 1H), 7.63 (dd, J = 2.2, 1.2 Hz, 1H), 7.49 – 7.33 (m, 1H), 6.44
(d, J = 1.0 Hz, 1H), 3.90 (d, J = 1.2 Hz, 3H), 3.47 – 3.39 (m, 2H), 2.72 – 2.54 (m, 2H). 13C
NMR (125 MHz, CDCl3 and CD3OD) δ 170.52, 162.40, 157.48, 141.32, 134.74, 134.42,
131.43, 122.78, 116.73, 114.47, 113.56, 106.14, 102.72, 52.64, 36.99, 28.77. HRMS (FAB)
m/z [M+Na+] for C17H14Br2ClNO5Na: 527.8927, found 527.8935.
methyl 3-chloro-2-(3-((3,5-dichlorophenyl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (55)—19 mg, 91% yield, white solid. 1H NMR (400 MHz, CDCl3):
δ 11.07 (s, 1 H), 7.51 (d, J = 1.88 Hz, 2 H), 7.29 (s, 1 H), 7.11 (t, J = 1.7 Hz, 1 H), 6.60 (s, 1
H), 6.13 (s, 1 H), 3.98 (s, 1 H), 3.52–3.43 (m, 2 H), 2.75–2.49 (m, 2 H). 13C NMR (125
MHz, CDCl3 and CD3OD): δ 170.73, 170.50, 162.48, 157.22, 141.80, 139.98, 135.30,
124.08, 117.85, 114.43, 106.49, 102.87, 52.77, 36.52, 28.62. HRMS (FAB) m/z [M+Na+]
for C17H14Cl3NO5Na: 439.9830, found 439.9840.
methyl 2-(3-((4-bromo-3-chlorophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (56)—24 mg, 89% yield, white solid. 1H NMR (500 MHz,
(CD3)2CO) δ 8.12 (d, J = 2.5 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 8.8, 2.5 Hz,
1H), 6.52 (s, 1H), 3.96 (s, 3H), 3.50 – 3.37 (m, 2H), 2.80 – 2.63 (m, 2H). 13C NMR (125
MHz, (CD3)2CO) δ 170.45, 170.32, 161.23, 157.73, 141.96, 140.00, 133.72, 120.46, 119.04,
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114.46, 113.91, 107.27, 102.20, 52.01, 35.87, 27.84. HRMS (FAB) m/z [M+Na+] for
C17H14BrCl2NO5Na: 483.9432; found, 398.9333.
methyl 2-(3-((2-bromo-3-chlorophenyl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (57)—23 mg, 72% yield, white amorphous solid: 1H NMR (500
MHz, CDCl3-MeOD) δ 8.14 (d, J = 7.9 Hz, 1H), 7.25 – 7.15 (m, 2H), 6.40 (d, J = 1.2 Hz,
1H), 3.90 (d, J = 1.2 Hz, 3H), 3.46 – 3.37 (m, 3H), 2.72 – 2.62 (m, 2H); 13C NMR (CDCl3-
MeOD, 125 MHz): δ 170.9, 170.6, 162.0, 158.1, 141.3, 137.3, 134.8, 128.5 (2), 125.6,
120.2, 114.7, 105.9, 102.5, 52.5, 36.8, 28.7; (FAB) m/z [M + Na+] for C17H14BrCl2NO5Na:
483.9330; found, 483.9327.
methyl 3-chloro-2-(3-((6-chloropyridin-2-yl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (58)—27 mg, 70% yield, white amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 10.88 (1H, br s), 9.48 (1H, br s)8.09 (dd, J = 8.2, 1.8 Hz, 1H), 7.80 –
7.58 (m, 1H), 7.00 (dd, J = 7.9, 1.7 Hz, 1H), 6.63 – 6.10 (m, 1H), 3.93 (s, 3H), 3.46 – 3.10
(m, 2H), 2.91 – 2.55 (m, 2H); 13C NMR (125 MHz, (CD3)2CO) δ 172.1, 171.5, 158.8,
153.3, 149.6, 143.1, 142.2, 119.9 (2), 115.0, 112.8, 108.3, 103.3, 53.1, 36.7, 28.8; (FAB) m/z
[M + Na+] for C16H14Cl2N2O5Na: 407.0174; found, 407.0177.
methyl 2-(3-((5-bromopyridin-2-yl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (59)—29 mg, 68% yield, white amorphous solid: 1H NMR (500
MHz, CDCl3-MeOD) δ 8.31 – 8.19 (m, 1H), 8.19 – 8.05 (m, 1H), 7.84 – 7.71 (m, 1H), 6.54
– 6.28 (m, 1H), 3.94 (s, 3H), 3.42 – 3.35 (m, 2H), 2.63 (dq, J = 12.7, 3.8, 2.1 Hz, 2H); 13C
NMR (CDCl3-MeOD, 125 MHz): δ 171.5, 170.9, 162.1, 158.2, 150.2, 148.6, 141.6, 141.0,
115.5, 114.8, 114.5, 106.1, 102.6, 52.6, 36.4, 28.3. (FAB) m/z [M + Na+] for
C16H14BrClN2O5Na: 450.9672; found, 450.9681.
methyl 3-chloro-2-(3-((4-chloropyridin-2-yl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (60)—16 mg, 64% yield, white solid. 1H NMR (500 MHz,
(CD3)2CO) δ 8.41 (dd, J = 2.0, 0.6 Hz, 1H), 8.28 (dd, J = 5.3, 0.6 Hz, 1H), 7.19 (dd, J = 5.3,
1.9 Hz, 1H), 6.55 (s, 1H), 3.99 (s, 3H), 3.56 – 3.42 (m, 2H), 2.98 – 2.81 (m, 2H). 13C NMR
(125 MHz, (CD3)2CO) δ 172.16, 171.34, 162.41, 158.69, 154.30, 150.12, 145.43, 142.93,
120.15, 113.98, 108.12, 103.20, 52.93, 36.62, 28.62. HRMS (FAB) m/z [M+Na+] for
C16H14Cl2N2O5Na: 407.0280; found, 407.0766.
methyl 3-chloro-2-(3-((3-chloropyridin-2-yl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (61)—21 mg, 55% yield, white amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 8.36 (dd, J = 4.7, 1.6 Hz, 1H), 7.92 (dd, J = 8.0, 1.6 Hz, 1H), 7.27 (ddd,
J = 8.0, 4.7, 0.6 Hz, 1H), 6.52 (s, 1H), 3.97 (s, 3H), 3.55 – 3.39 (m, 2H), 3.00 – 2.76 (m,
2H). 13C NMR (125 MHz, (CD3)2CO) δ 171.4, 171.28, 158.6, 149.3, 147.5, 143.2 (2),
139.3, 122.9 (2), 114.8, 108.14, 103.1, 52.9, 35.9, 28.8; (FAB) m/z [M + Na+] for
C16H14Cl2N2O5Na: 407.0174; found 407.0174.
methyl 2-(3-((3-bromopyridin-2-yl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (62)—31 mg, 71% yield, white amorphous solid: 1H NMR (400
MHz, CDCl3-MeOD) δ 8.47 (dd, J = 4.7, 1.6 Hz, 1H), 7.98 (dd, J = 8.0, 1.6 Hz, 1H), 7.27 –
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7.22(m, 1H), 6.34 (s, 1H), 3.85 (s, 3H), 3.35 – 3.29 (m, 2H), 2.91 – 2.65 (m, 2H). 13C NMR
(125 MHz, CDCl3,): δ 172.8, 170.0, 161.2, 156.9, 149.7, 147.8, 141.7, 140.6, 124.9, 120.3,
113.8, 105.0, 101.4, 51.6, 36.3, 26.6. (FAB) m/z [M + Na+] for C16H14BrClN2O5Na:
450.9672; found, 450.9677.
methyl 3-chloro-2-(3-((5-chlorothiazol-2-yl)amino)-3-oxopropyl)-4,6-
dihydroxybenzoate (63)—17 mg, 44.7% yield, pale yellow amorphous solid: 1H NMR
(400 MHz, (CD3)2CO) δ 7.34 (s, 1H), 6.52 (s, 1H), 5.63 (s, 1H), 3.94 (s, 3H), 3.55 – 3.31
(m, 2H), 2.93 – 2.71 (m, 2H). 13C NMR (125 MHz, CDCl3-MeOD): δ 170.8 (2), 162.0,
158.1, 147.8, 141.8, 136.9, 129.5, 126.6, 125.3, 124.6, 120.9, 114.8, 106.2, 52.5, 30.8,
26.2; . HRMS (FAB) m/z [M +H+] for C14H13Cl2N2O5S: 390.9922; found, 390.9913.
methyl 2-(3-((5-bromothiazol-2-yl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (64)—36 mg, 83% yield, gray amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 7.33 (s, 1H), 6.52 (s, 1H), 3.94 (s, 2H), 3.60 – 3.28 (m, 2H), 2.93 – 2.78
(m, 2H). 13C NMR(125 MHz, (CD3)2CO): δ 170.9, 170.9, 162.2, 159.6, 158.1, 141.4, 137.7,
114.9, 106.1, 102.7 (2), 52.7, 34.7, 28.1; HRMS (FAB) m/z [M +Na+] for
C14H12BrClN2O5SNa: 456.9237; found, 456.9238.
methyl 2-(3-((5-bromo-1,3,4-thiadiazol-2-yl)amino)-3-oxopropyl)-3-chloro-4,6-
dihydroxybenzoate (65)—12 mg, 28% yield, gray amorphous solid: 1H NMR (500
MHz, (CD3)2CO) δ 6.53 (s, 1H), 3.94 (s, 4H), 3.59 – 3.43 (m, 2H), 3.05 – 2.84 (m, 2H). 13C
NMR (125 MHz, (CD3)2CO): δ 171.7, 161.6, 158.7, 142.2, 134.8, 130.6, 114.9, 108.1,
103.3, 79.3, 53.0, 35.2, 21.1. HRMS (FAB) m/z [M +H+] for C13H12BrClN3O5S: 435.9370;
found, 435.9377.
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(A) Structures of natural product Hsp90 inhibitors GDA and RDC, chimeric inhibitor RDA,
and Grp94-selective inhibitor BnIm; (B) Co-crystal structure of RDA bound to Hsp90
(PDB: 2FXS); (C) Co-crystal structure of RDA bound to Grp94 (PDB: 2GFD)
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Optimization of Amide Linker and Hydrophobic Moiety.a–d
a Compounds 2–6 (25 µM) were incubated with cGrp94 and FITC-GDA (tracer) for 24 h
before fluorescence polarization values were determined. b DMSO (1%) served as a negative
control (vehicle), and GDA (50 nM) served as the positive control. c All compounds tested
at 25 µM. d All compounds were tested in triplicate.
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Evaluation of 2-Phenyl Substitutions a–d
a Compounds 7–15 (25 µM) were incubated with cGrp94 and FITC-GDA (tracer) for 24 h
before fluorescence polarization values were determined. b DMSO (1%) served as a negative
control (vehicle), and GDA (50 nM) served as the positive control. c All compounds tested
at 25 µM. d All compounds were tested in triplicate.
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Evaluation of 3-Phenyl Substitutionsa–d
a Compounds 16–24 (25 µM) were incubated with cGrp94 and FITC-GDA (tracer) for 24 h
before fluorescence polarization values were determined. b DMSO (1%) served as a negative
control (vehicle), and GDA (50 nM) served as the positive control. c All compounds tested
at 25 µM. d All compounds were tested in triplicate.
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Evaluation of 4-Phenyl Substitutionsa–d
a Compounds 25–37 (25 µM) were incubated with cGrp94 and FITC-GDA (tracer) for 24 h
before fluorescence polarization values were determined. b DMSO (1%) served as a negative
control (vehicle), and GDA (50 nM) served as the positive control. c All compounds tested
at 25 µM. d All compounds were tested in triplicate.
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Evaluation of Heterocyclic Amidesa–d
a Compounds 38–48 (25 µM) were incubated with cGrp94 and FITC-GDA (tracer) for 24 h
before fluorescence polarization values were determined. b DMSO (1%) served as a negative
control (vehicle), and GDA (50 nM) served as the positive control. c All compounds tested
at 25 µM. d All compounds were tested in triplicate.
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Evaluation of Amides 49–53a–d
a Compounds 49–53 (25 µM) were incubated with cGrp94 and FITC-GDA (tracer) for 24 h
before fluorescence polarization values were determined. b DMSO (1%) served as a negative
control (vehicle), and GDA (50 nM) served as the positive control. c All compounds tested
at 25 µM. d All compounds were tested in triplicate.
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Inhibition of Grp94 and Hsp90a at 25 µM Illustrating Grp94-Selectivitya–e.
a Compounds (25 µM) were incubated with cGrp94 or Hsp90a and FITC-GDA (tracer) for
24 h before fluorescence polarization values were determined. b DMSO (1%) served as a
negative control (vehicle), and GDA (50 nM) served as the positive control. c All
compounds tested at 25 µM. d All compounds were tested in triplicate
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Combinations of Key Features and their Grp94 Inhibitiona–d
a Compounds 54–65 (25 µM) were incubated with cGrp94 and FITC-GDA (tracer) for 24 h
before fluorescence polarization values were determined. b DMSO (1%) served as a negative
control (vehicle), and GDA (50 nM) served as the positive control. ND=not determined. c
All compounds tested at 25 µM. d All compounds were tested in triplicate.
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a,b Inhibition of MDA-MB-231 Cell Migration by Compounds 38 and 46a–b
a MDA-MB-231 cells were incubated for 24 h prior to compound addition. b Cells were
incubated for 16 h and 24 h at 37°C with the respective conjugate indicated above (2.5 µM).
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Effect of compounds 38 and 46 on Grp94 conformation. MDA-MB-231 cells were treated
with the indicated concentrations of 38 and 46 (concentrations listed are µM) or radicicol (R
15 µM) overnight, and cell lysates were immunoprecipitated with the conformational-
specific antibody 9G10 and subsequently were immunoblotted for Grp94. Lower panel,
immunoblot of whole cell lysates with 9G10.
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Western blot analysis of IGF-II secretion into MDA-MB-231 breast cancer cell media upon
treatment with amides 38 and 46. H (high) represents a concentration equal to 10 µM. L
(low) represents a concentration equal to 1 µM. Radicicol (RDC, 15 µM) and
dimethylsulfoxide (DMSO, 100%) were employed as positive and negative controls,
respectively.
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Western blot analyses of Hsp90-dependent client proteins from MDA-MB-231 breast cancer
cell lysate upon treatment with amides 38 and 46. H (high) represents a concentration equal
to 5-fold the anti-proliferative IC50 value. L (low) represents a concentration equal to 0.5-
fold the anti-proliferative IC50 value. Radicicol (RDC, 15 µM) and dimethylsulfoxide
(DMSO, 100%) were employed as positive and negative controls, respectively.
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Effect of compounds 38 and 46 on Grp94 conformation. RPMI 8226 cells were treated with
the indicated concentrations of 38 and 46 (concentrations listed are µM) or radicicol (R 15
µM) overnight, and cell lysates were immunoprecipitated with the conformational-specific
antibody 9G10 and subsequently were immunoblotted for Grp94. Lower panel, immunoblot
of whole cell lysates with 9G10.
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Western blot analysis of IGF-II secretion into RPMI 8226 cell media upon treatment with
amides 38 and 46. H (high) represents a concentration equal to 2-fold the anti-proliferative
IC50 value. L (low) represents a concentration equal to 0.25-fold the anti-proliferative IC50
value. Radicicol (RDC, 15 µM) and dimethylsulfoxide (DMSO, 100%) were employed as
positive and negative controls, respectively.
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Western blot analyses of Hsp90-dependent client proteins from RPMI 8226 multiple
myeloma cell lysate upon treatment with amides 38 and 46. H (high) represents a
concentration equal to 5-fold the anti-proliferative IC50 value. L (low) represents a
concentration equal to 0.5-fold the anti-proliferative IC50 value. Radicicol (RDC, 15 µM)
and dimethylsulfoxide (DMSO, 100%) were employed as positive and negative controls,
respectively.
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Summary of SAR for Grp94 Binding of RDA Based Derivatives.
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Development of RDA-Based Grp94 Inhibitors
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Table 1









Compounds 8, 17, 27, 38, 46 and 47 were incubated with cGrp94 and FITC-GDA (tracer) for 24 h before fluorescence polarization values were
determined.
b
DMSO (1%) served as a negative control (vehicle), and GDA (50 nM) served as the positive control.
c
All compounds were tested in triplicate.
d
Millipolarization (mP) units were used to determine % tracer bound.
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Table 2





RPMI 8226 cells were incubated for 24 h prior to drug addition.
b
Cells were incubated for 72 h at 37°C in 5% CO2 with the respective conjugate.
c
All experiments were performed in triplicate.
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